Pharmaceuticals
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today...
2022-01-12 20:43
3193
Bionomics Limited participated in the H.C Wainwright BioConnect Conference
ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually fromJanuary 10-13, 2022. Dr Errol De Souza, Executive C...
2022-01-12 19:00
2809
PostEra Closes $24M in New Financing to Advance Drug Discovery
BOSTON, Jan. 11, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of ...
2022-01-11 22:00
4016
Cambrex Celebrates its 40th Anniversary while Investing over $100 million in New Drug Substance Manufacturing Capacity
EAST RUTHERFORD, N.J., Jan. 11, 2022 /PRNewswire/ -- Cambrex recently celebrated the 40th anniversary of its founding in 1981. Following forty years of growth and transformation into a leading global contract development and manufacturing organization (CDMO), Cambrex continues its commitment to ...
2022-01-11 21:30
3435
Qilian International Holding Group Limited Releases 2022 Chairman Letter
JIUQUAN, China, Jan. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today released a letter to shareholders from the Chairman of the Com...
2022-01-11 20:00
2456
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...
2022-01-11 16:30
4483
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...
2022-01-11 15:15
3267
SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections
COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabli...
2022-01-11 14:29
1827
Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy
SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy
2022-01-11 09:30
3259
Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod
* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...
2022-01-11 09:00
3195
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT051...
2022-01-11 08:30
4274
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmace...
2022-01-11 05:30
5092
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China andSHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage ...
2022-01-11 05:30
3790
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced thatthe United States Food and Drug Administration (FDA)...
2022-01-10 21:50
4089
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines
2022-01-10 21:35
5201
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma Report also examines key therapeutic development areas to watch including mRNA, CRISPR, AI-driven drug discovery and more LONDON, Jan. 10, 2022 /...
2022-01-10 16:00
3340
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from10-13 January 2022. The co...
2022-01-07 21:00
5138
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company's latest development. Details are as follows: Morgan Stan...
2022-01-07 08:30
2833
Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
HONG KONG and NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.Alex Zhavoronkov, Founder and Chief Executive Officer of I...
2022-01-07 03:55
2741
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases
SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure has been conducting j...
2022-01-06 22:00
2308
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Noah Holdings Limited Announces Changes to the Board and Board Committees
2026-08-29 04:30
7430